Pairing a long-acting amylin analog with semaglutide was supposed to be Novo Nordisk's answer to tirzepatide. The REDEFINE program shows a real, large effect — and a head-to-head trial showing it still isn't quite enough.
Obesity
-
CagriSema and the Amylin Comeback -
MariTide and the Antagonist Paradox Amgen's maridebart cafraglutide blocks the same receptor tirzepatide activates, still produces close to 20% weight loss, and does it from a monthly injection instead of a weekly one — an antibody-format peptide drug with a genuinely unresolved mechanism and a real tolerability problem.
-
Petrelintide and the Amylin-Only Bet Zealand Pharma's petrelintide drops the GLP-1 component entirely and still produced 10.7% weight loss with placebo-like tolerability in its lead Phase 2 trial — a real test of whether amylin alone can compete with the incretin class, backed by a $5.3 billion Roche partnership.
-
Retatrutide: The Triple Agonist Pushing Past Tirzepatide Retatrutide's third receptor mechanism has produced the largest weight-loss and liver-fat numbers of any peptide therapeutic tested so far, and an eight-trial Phase 3 program to match. It also has a documented heart-rate signal the earlier drugs in its class don't carry.
-
Survodutide and Mazdutide: The Glucagon Bet Two GLP-1/glucagon dual agonists, developed an ocean apart by Boehringer Ingelheim and Innovent Biologics, are testing whether adding back a hormone that normally raises blood sugar can still produce a net metabolic win.